Sacituzumab govitecan vs standard chemotherapy in triple negative breast cancer

For metastatic triple negative breast cancer that has already been treated with at least two earlier treatments, at least one of them for metastatic disease, sacituzumab govitecan has been compared directly with standard single chemotherapy drugs. The main study, called ASCENT, compared it with a chemotherapy chosen by the doctor: eribulin, vinorelbine, capecitabine or gemcitabine. People given sacituzumab govitecan did better on every main measure. The cancer shrank in about a third of them, compared with about one in twenty on chemotherapy. The typical time before the cancer grew was roughly five months, against under two months. The typical survival was about a year, against under seven months. These are averages from a trial and do not predict any one person's result, but the difference was large enough to change practice in many countries. The trade-off is in side effects and practicalities. Sacituzumab govitecan causes more loose motions, low white cell counts and hair loss than some chemotherapy tablets, and it needs two hospital drips in every three-week cycle. Standard chemotherapy drugs are older, more widely available and far less expensive, and some can be taken as tablets. The right choice depends on your earlier treatments, general health, test results, access to the medicine and what matters most to you.

It worked better in the key study

More shrinkage, longer control and longer survival than single chemotherapy.

Side effects differ

Loose motions and low counts are more common, while nerve damage is less of a concern.

Access matters

Cost and availability shape real-world choices in India.

The study results were clear, but they come with limits that are worth understanding.

It applies to a specific group

The trial included people with triple negative cancer who had already had several treatments. It does not show how the drug compares as a first treatment.

Averages hide wide variation

Some people did far better than the averages, and some did not benefit at all.

The gains are measured in months

Neither option makes metastatic triple negative cancer go away for good.

What this page cannot tell you

It cannot say which option is right for you. That depends on details only your oncologist can weigh.

Metastatic triple negative breast cancer is usually treated with several options in turn.

First treatment

Chemotherapy is usually used first, with immunotherapy added for cancers that test positive for PD-L1. Studies are testing sacituzumab govitecan earlier, and guidance may change.

Later treatments

After the cancer grows on earlier treatment, sacituzumab govitecan is a preferred option where available. Other chemotherapy drugs remain useful after it, or instead of it.

Special situations

A BRCA mutation may allow a PARP inhibitor tablet, and clinical trials may be available at any stage.